Definium Therapeutics (DFTX) Tax Provisions (2021 - 2022)
Definium Therapeutics (DFTX) posted quarterly Tax Provisions of $224000.0 for Q4 2022, up 101.13% year-over-year from $111369.4 in Q4 2021, and up 101.13% quarter-over-quarter from -$19.8 million in Q4 2021.
Definium Therapeutics (DFTX) Tax Provisions (2021 - 2022) Analysis & Trends
Definium Therapeutics (DFTX) has reported Tax Provisions for 2 consecutive years, with $224000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Tax Provisions rose 101.13% year-over-year to $224000.0; the TTM figure through Dec 2022 stood at -$19.6 million (changed N/A YoY), while the FY2022 annual figure was $224000.0, up 101.13% from the prior year.
- Tax Provisions advanced to $224000.0 in Q4 2022 per DFTX's latest filing, from -$19.8 million in the prior quarter.
- Across five years, Tax Provisions topped out at $224000.0 in Q4 2022 and bottomed at -$19.8 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 224,000.00 |
| Dec 31, 2021 | -19.78 Mn |